Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.18
â–²(27.86% Upside)
Action:ReiteratedDate:03/19/26
The score is primarily constrained by weak financial performance (declining revenue, persistent losses, and high leverage). Technicals provide the main support, with the stock trading above key moving averages and generally constructive momentum. Valuation remains a risk factor because the negative P/E reflects ongoing unprofitability and dividend yield is unavailable.
Positive Factors
Focused colorectal screening program
Rhythm's clear product focus on Colostat targets population colorectal screening, a structurally growing public-health area. A dedicated, clinically oriented diagnostic can secure durable adoption in screening programs and clinical pathways, enabling steady volume growth if uptake rises.
Negative Factors
Steep recent revenue decline
A near-43% revenue decline erodes scale needed for diagnostics commercialization and weakens the firm's ability to leverage fixed costs. Sustained top-line contraction limits reinvestment in marketing, clinical adoption, and R&D, making long-term commercialisation and margin recovery more challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused colorectal screening program
Rhythm's clear product focus on Colostat targets population colorectal screening, a structurally growing public-health area. A dedicated, clinically oriented diagnostic can secure durable adoption in screening programs and clinical pathways, enabling steady volume growth if uptake rises.
Read all positive factors
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$62.14M
Dividend YieldN/A
Average Volume (3M)462.98K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth56.42%
CountryAU
Employees23
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,225,860
10 Day Avg. Volume510,821
30 Day Avg. Volume462,976
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)22.03
Price to Sales (P/S)4.56
P/FCF Ratio-4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Company Description
Rhythm Biosciences Limited, a transformative predictive cancer diagnostics technology company in Australia and internationally. The company engages in developing and commercializing medical diagnostics technology. It develops ColoSTAT, a blood tes...
How the Company Makes Money
null...
Rhythm Biosciences Ltd. Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.37K | 3.19M | 1.69M | 3.10M | 2.43M | 1.11M |
| Gross Profit | -4.57M | 2.97M | -1.36M | 2.91M | -101.48K | 961.86K |
| EBITDA | -7.98M | -3.53M | -8.35M | -11.11M | -11.10M | -6.46M |
| Net Income | -6.68M | -3.83M | -6.86M | -8.22M | -8.79M | -6.61M |
Balance Sheet | ||||||
| Total Assets | 3.10M | 2.83M | 1.52M | 7.70M | 8.44M | 3.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.73M | 1.48M | 754.50K | 4.17M | 7.60M | 2.27M |
| Total Debt | 262.44K | 1.11M | 163.82K | 84.61K | 170.14K | 0.00 |
| Total Liabilities | 955.41K | 2.17M | 651.54K | 1.82M | 1.07M | 1.36M |
| Stockholders Equity | 2.14M | 659.89K | 867.17K | 5.87M | 7.37M | 1.71M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -2.94M | -6.22M | -7.06M | -6.24M | -5.47M |
| Operating Cash Flow | -6.11M | -2.92M | -6.14M | -6.96M | -6.21M | -5.40M |
| Investing Cash Flow | -24.23K | -582.96K | -82.28K | -99.12K | -27.01K | -68.27K |
| Financing Cash Flow | 3.41M | 4.19M | 2.80M | 3.63M | 11.85M | 5.90M |
Rhythm Biosciences Ltd. Technical Analysis
Neutral
0.14
Price Trends
0.20
Negative
0.15
Positive
0.12
Positive
Market Momentum
>-0.01
Positive
45.00
Neutral
31.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHY, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.20, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 31.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RHY.
Rhythm Biosciences Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$62.14M | -4.75 | -476.27% | ― | ― | 56.42% | |
46 Neutral | AU$168.57M | -7.39 | -164.12% | ― | 12.96% | 40.81% | |
44 Neutral | AU$5.67M | -0.55 | -184.98% | ― | -56.35% | 42.80% | |
42 Neutral | AU$33.18M | -2.45 | -164.22% | ― | ― | 23.85% | |
41 Neutral | AU$18.17M | -2.23 | -23.93% | ― | 62.81% | 16.37% | |
38 Underperform | AU$48.57M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:RHY
Rhythm Biosciences Ltd.
0.18
0.11
157.14%
AU:GTG
Genetic Technologies
0.04
0.00
0.00%
AU:BDX
BCAL Diagnostics Limited
0.09
0.00
0.00%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.21
0.19
950.00%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.34
-80.95%
AU:IIQ
Inoviq Ltd
0.35
-0.04
-9.21%
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences updates market on director’s lapsed unlisted options
Apr 7, 2026
Rhythm Biosciences has reported a change in Director David Atkins’ interests in the company’s securities, following the lapse of 2,000,000 unlisted options held directly and indirectly, including via Beacon Advisors Ltd. After this cha...
Rhythm Biosciences Plans Issue of 18.8 Million New Shares
Apr 2, 2026
Rhythm Biosciences has announced a proposed issue of up to 18,834,007 new fully paid ordinary shares, to be conducted as a placement or other form of security issue. The new securities are expected to be issued on 23 April 2026, signalling a plann...
Rhythm Biosciences Seeks ASX Quotation for Nearly 2 Million New Shares
Apr 2, 2026
Rhythm Biosciences Limited has applied for quotation of 1,951,494 new fully paid ordinary shares on the Australian Securities Exchange, to be issued on 2 April 2026. The additional securities arise from the exercise or conversion of existing optio...
Rhythm Biosciences Confirms RHYO Options Deadline and Underwriting Terms
Mar 31, 2026
Rhythm Biosciences has confirmed that the deadline for exercising its RHYO options is 5:00 pm Melbourne time on 31 March 2026 and reports that a significant volume of options has already been exercised. The company’s underwriting agreement w...
Rhythm Biosciences Doubles ColoSTAT Test Network and Expands Clinician Access Program
Mar 29, 2026
Rhythm Biosciences has accelerated the commercial roll-out of its ColoSTAT colorectal cancer blood test in Australia through its partnership with 4Cyte Pathology, more than doubling activated commercial collection centres to seventy-eight across t...
Rhythm Biosciences Seeks ASX Quotation for 2.9 Million New Shares
Mar 27, 2026
Rhythm Biosciences has applied for quotation on the ASX of 2,906,063 new ordinary fully paid shares, which are scheduled to be issued and quoted on March 27, 2026. The additional securities, arising from the exercise or conversion of existing inst...
Rhythm Biosciences Seeks ASX Quotation for 1.96 Million New Shares
Mar 20, 2026
Rhythm Biosciences has applied for quotation of 1,961,158 new fully paid ordinary shares on the ASX, with an issue date of March 20, 2026. The additional securities, arising from the exercise or conversion of existing options or other convertible ...
Rhythm Biosciences Scales ColoSTAT Rollout via 4Cyte Pathology Network
Mar 17, 2026
Rhythm Biosciences has accelerated the commercial rollout of its ColoSTAT colorectal cancer blood test by activating its first commercial blood collection network through 4Cyte Pathology across major Australian cities. An initial 38 collection sit...
Rhythm Biosciences Issues Cautionary Business Update
Mar 17, 2026
Rhythm Biosciences Limited has issued a business update presentation dated 18 March 2026, outlining information intended solely for general informational purposes and not as investment advice. The company stresses that various aspects of its work ...
Rhythm Biosciences Seeks ASX Quotation for Additional Ordinary Shares
Mar 13, 2026
Rhythm Biosciences Ltd has applied for quotation on the ASX of 235,134 additional ordinary fully paid shares, designated under the code RHY. The new securities arise from the exercise or conversion of existing options or other convertible instrume...
Rhythm Biosciences launches commercial operations with first ColoSTAT test sale
Mar 10, 2026
Rhythm Biosciences has completed the first commercial sale of its ColoSTAT blood-based colorectal cancer test, marking the formal start of its clinical diagnostic testing operations. The test was ordered for a symptomatic patient, collected by par...
Rhythm Biosciences Wins NATA Accreditation for ColoSTAT Cancer Test
Mar 8, 2026
Rhythm Biosciences has secured National Association of Testing Authorities accreditation for its ColoSTAT blood-based colorectal cancer test within its ISO 15189:2022-certified Parkville laboratory. This recognition confirms that both the facility...
Rhythm Biosciences Seeks ASX Quotation for New Ordinary Shares
Mar 5, 2026
Rhythm Biosciences has applied to the ASX for quotation of 90,842 new fully paid ordinary shares. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly increasing the company...
Rhythm Biosciences inks first Southeast Asia geneType distribution deal
Mar 3, 2026
Rhythm Biosciences has signed a 12‑month supply and distribution agreement with UK-based Digistain Limited to commercialise its geneType genetic test portfolio in Southeast Asia, starting with the Philippines as the initial launch market. Th...
Rhythm Biosciences Issues New Shares and Lodges Cleansing Notice
Feb 27, 2026
Rhythm Biosciences has issued 413,793 new ordinary shares on 27 February 2026 and lodged a cleansing notice under section 708A(5)(e) of the Corporations Act, confirming the issuance was made without a disclosure document. The company states it is ...
Rhythm Biosciences Seeks ASX Quotation for 413,793 New Shares
Feb 27, 2026
Rhythm Biosciences Ltd. has applied for quotation of 413,793 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 27 February 2026. The additional securities, linked to a previously announced transaction, wil...
Rhythm Biosciences Seeks ASX Quotation for Additional Ordinary Shares
Feb 27, 2026
Rhythm Biosciences Ltd. has applied to the ASX for quotation of 61,901 new ordinary fully paid shares, which are being issued following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted s...
Rhythm Biosciences Secures Up to $6m Option Underwriting for Cancer Diagnostics Rollout
Feb 24, 2026
Rhythm Biosciences has secured a binding underwriting agreement with CPS Capital Group to partially underwrite the exercise of its listed options, guaranteeing a minimum of $4.5 million and up to $6 million in funding before costs. The underwriter...
Rhythm Biosciences Seeks ASX Quotation for 300,137 New Shares
Feb 20, 2026
Rhythm Biosciences Limited has applied for quotation on the ASX of 300,137 new fully paid ordinary shares under code RHY. The new securities, issued on 20 February 2026 following the exercise or conversion of existing options or other convertible ...
Rhythm Biosciences Begins Commercial Rollout of ColoSTAT with First Physician Enrolment
Feb 10, 2026
Rhythm Biosciences has launched its ColoSTAT Access Program in Australia, enrolling the first physician participant and formally moving the blood-based colorectal cancer test from clinical development into structured commercial deployment. The pro...
Rhythm Biosciences reminds investors of looming RHYO option expiry
Feb 10, 2026
Rhythm Biosciences has reminded holders of its ASX-listed RHYO options that these securities must be exercised by 5.00pm Melbourne time on 31 March 2026 at an exercise price of $0.20 per option, with each option converting into one fully paid RHY ...
Rhythm Biosciences Secures Quansys as Commercial Manufacturer for ColoSTAT® Kits
Feb 2, 2026
Rhythm Biosciences has signed a multi-year commercial supply agreement with US-based Quansys Biosciences to manufacture ColoSTAT® consumable reagent kits at commercial scale. The deal formalises a two-year collaboration and secures ISO13485-c...
Rhythm Biosciences Partners with AGRF to Build Australian Hub for GeneType Diagnostics
Jan 28, 2026
Rhythm Biosciences has entered a strategic partnership with the Australian Genome Research Facility to establish an Australian-based reference laboratory for its geneType genotyping services, enabling local processing of more than 100,000 tests an...
Rhythm Biosciences Taps CancerIQ Platform to Fast-Track US Rollout of geneType Cancer Risk Tests
Jan 27, 2026
Rhythm Biosciences has entered a strategic partnership with US-based digital oncology platform CancerIQ, integrating its geneType™ Cancer Risk Assessment into a cloud-based system already deployed across more than 65 health systems and 345 c...
Rhythm Biosciences Launches ColoSTAT® Commercialisation and Accelerates Global Cancer Test Push
Jan 22, 2026
Rhythm Biosciences has begun commercialising its ColoSTAT® blood test in Australia after securing ISO 15189:2022 accreditation, marking its first revenue-generating product and aiming to improve triage for more than 800,000 symptomatic colono...
Rhythm Biosciences’ ColoSTAT Blood Test Clinically Validated for Colorectal Cancer Triage
Jan 20, 2026
Rhythm Biosciences has announced peer‑reviewed publication of clinical validation data for its first-generation ColoSTAT singleplex blood test for colorectal cancer, showing 81.3% sensitivity and 91% specificity in a 989‑patient, multi...
Rhythm Biosciences Issues 1 Million New Shares Under Cleansing Notice
Jan 16, 2026
Rhythm Biosciences has issued 1,000,000 new ordinary shares on 16 January 2026 and has lodged a cleansing notice confirming that the shares were issued without a prospectus under the Corporations Act disclosure exemptions. The company states it re...
Rhythm Biosciences Seeks ASX Quotation for 1 Million New Shares
Jan 16, 2026
Rhythm Biosciences Limited has applied to the ASX for quotation of 1,000,000 new ordinary fully paid shares, with an issue date of 16 January 2026. The additional securities, issued under a previously announced transaction, will expand the company...
Rhythm Biosciences Employee Performance Rights Lapse, Trimming Potential Future Share Issuance
Jan 14, 2026
Rhythm Biosciences has disclosed the cessation of 750,000 fully paid ordinary employee performance rights (ASX code: RHYAR), which lapsed after the conditions attached to those rights were not met or became incapable of being satisfied as of 13 Ja...
Rhythm Biosciences Launches Enhanced GeneType Test to Sharpen Colorectal Cancer Risk Stratification
Jan 13, 2026
Rhythm Biosciences has commercially launched an enhanced version of its geneType colorectal cancer risk assessment test, which now integrates genetic, clinical and lifestyle factors, along with gender-specific variables, to deliver improved risk s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.